Terms: = Head and neck cancer AND HER1, YOR227W
55 results:
1. HER2 and HER3 as Therapeutic Targets in head and neck cancer.
Saddawi-Konefka R; Schokrpur S; Lui AJ; Gutkind JS
Cancer J; 2022 Sep-Oct 01; 28(5):339-345. PubMed ID: 36165721
[TBL] [Abstract] [Full Text] [Related]
2. Emerging tyrosine kinase inhibitors for head and neck cancer.
Long Z; Grandis JR; Johnson DE
Expert Opin Emerg Drugs; 2022 Sep; 27(3):333-344. PubMed ID: 36131561
[TBL] [Abstract] [Full Text] [Related]
3. Parathyroid hormone-related peptide and parathyroid hormone-related peptide receptor type 1 in locally advanced laryngeal cancer as prognostic indicators of relapse and survival.
Almadori G; Coli A; De Corso E; Mele DA; Settimi S; Di Cintio G; Brigato F; Scannone D; Lauriola L; Ranelletti FO
BMC Cancer; 2022 Jun; 22(1):704. PubMed ID: 35761298
[TBL] [Abstract] [Full Text] [Related]
4. Recent advances in the development of EGFR degraders: PROTACs and LYTACs.
Hong D; Zhou B; Zhang B; Ren H; Zhu L; Zheng G; Ge M; Ge J
Eur J Med Chem; 2022 Sep; 239():114533. PubMed ID: 35728507
[TBL] [Abstract] [Full Text] [Related]
5. The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein.
Lucas LM; Dwivedi V; Senfeld JI; Cullum RL; Mill CP; Piazza JT; Bryant IN; Cook LJ; Miller ST; Lott JH; Kelley CM; Knerr EL; Markham JA; Kaufmann DP; Jacobi MA; Shen J; Riese DJ
Pharmacol Rev; 2022 Jan; 74(1):18-47. PubMed ID: 34987087
[TBL] [Abstract] [Full Text] [Related]
6. Nuclear HER3 expression improves the prognostic stratification of patients with her1 positive advanced laryngeal squamous cell carcinoma.
Almadori G; Coli A; De Corso E; Mele DA; Settimi S; Di Cintio G; Brigato F; Scannone D; Carey TE; Paludetti G; Lauriola L; Ranelletti FO
J Transl Med; 2021 Sep; 19(1):408. PubMed ID: 34579737
[TBL] [Abstract] [Full Text] [Related]
7. Mig6 not only inhibits EGFR and HER2 but also targets HER3 and HER4 in a differential specificity: Implications for targeted esophageal cancer therapy.
Zhong H; He J; Yu J; Li X; Mei Y; Hao L; Wu X
Biochimie; 2021 Nov; 190():132-142. PubMed ID: 34293452
[TBL] [Abstract] [Full Text] [Related]
8. Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines.
De Pauw I; Lardon F; Van den Bossche J; Baysal H; Fransen E; Deschoolmeester V; Pauwels P; Peeters M; Vermorken JB; Wouters A
Mol Oncol; 2018 Jun; 12(6):830-854. PubMed ID: 29603584
[TBL] [Abstract] [Full Text] [Related]
9. Development of epidermal growth factor receptor targeted therapy in pancreatic cancer.
Qing L; Qing W
Minerva Chir; 2018 Oct; 73(5):488-496. PubMed ID: 29397631
[TBL] [Abstract] [Full Text] [Related]
10. Expression and prognostic significance of human epidermal growth factor receptors 1, 2 and 3 in oesophageal and gastric adenocarcinomas preneoadjuvant and postneoadjuvant treatment.
Hedner C; Borg D; Nodin B; Karnevi E; Jirström K; Eberhard J
J Clin Pathol; 2018 May; 71(5):451-462. PubMed ID: 29138285
[TBL] [Abstract] [Full Text] [Related]
11. Dual "mAb" HER family blockade in head and neck cancer human cell lines combined with photon therapy.
Guy JB; Méry B; Ollier E; Espenel S; Vallard A; Wozny AS; Simonet S; Lauret A; Battiston-Montagne P; Ardail D; Alphonse G; Rancoule C; Rodriguez-Lafrasse C; Magné N
Sci Rep; 2017 Sep; 7(1):12207. PubMed ID: 28939847
[TBL] [Abstract] [Full Text] [Related]
12. Minichromosome maintenance protein 7 and geminin expression: Prognostic value in laryngeal squamous cell carcinoma in patients treated with radiotherapy and cetuximab.
Almadori G; Lauriola L; Coli A; Bussu F; Gallus R; Scannone D; Valentini V; Paludetti G; Carey TE; Ranelletti FO
Head Neck; 2017 Apr; 39(4):684-693. PubMed ID: 28032719
[TBL] [Abstract] [Full Text] [Related]
13. The prospect of patritumab for treating non-small cell lung cancer.
Horinouchi H
Expert Opin Biol Ther; 2016 Dec; 16(12):1549-1555. PubMed ID: 27744717
[TBL] [Abstract] [Full Text] [Related]
14. HER3 Expression Is a Marker of Tumor Progression in Premalignant Lesions of the Gastroesophageal Junction.
Ecker BL; Taylor L; Zhang PJ; Furth EE; Ginsberg GG; McMillan MT; Datta J; Czerniecki BJ; Roses RE
PLoS One; 2016; 11(8):e0161781. PubMed ID: 27559738
[TBL] [Abstract] [Full Text] [Related]
15. Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1 and 3 in Gastric and Esophageal Adenocarcinoma.
Hedner C; Borg D; Nodin B; Karnevi E; Jirström K; Eberhard J
PLoS One; 2016; 11(2):e0148101. PubMed ID: 26844548
[TBL] [Abstract] [Full Text] [Related]
16. Increased Expression of HER2, HER3, and HER2:HER3 Heterodimers in HPV-Positive HNSCC Using a Novel Proximity-Based Assay: Implications for Targeted Therapies.
Pollock NI; Wang L; Wallweber G; Gooding WE; Huang W; Chenna A; Winslow J; Sen M; DeGrave KA; Li H; Zeng Y; Grandis JR
Clin Cancer Res; 2015 Oct; 21(20):4597-606. PubMed ID: 26138066
[TBL] [Abstract] [Full Text] [Related]
17. Preclinical pharmacokinetics, pharmacodynamics, and efficacy of RG7116: a novel humanized, glycoengineered anti-HER3 antibody.
Meneses-Lorente G; Friess T; Kolm I; Hölzlwimmer G; Bader S; Meille C; Thomas M; Bossenmaier B
Cancer Chemother Pharmacol; 2015 Apr; 75(4):837-50. PubMed ID: 25702049
[TBL] [Abstract] [Full Text] [Related]
18. The expression of EGFR, cerbB2, p16, and p53 and their relationship with conventional parameters in squamous cell carcinoma of the larynx.
Şimşek H; Han Ü; Önal B; Şimişek G
Turk J Med Sci; 2014; 44(3):411-6. PubMed ID: 25558642
[TBL] [Abstract] [Full Text] [Related]
19. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
[TBL] [Abstract] [Full Text] [Related]
20. Effective targeting of the epidermal growth factor receptor (EGFR) for treating oral cancer: a promising approach.
Ribeiro FA; Noguti J; Oshima CT; Ribeiro DA
Anticancer Res; 2014 Apr; 34(4):1547-52. PubMed ID: 24692681
[TBL] [Abstract] [Full Text] [Related]
[Next]
